Literature DB >> 17034008

Glutathione S-transferase polymorphisms and onset age in alpha-synuclein A53T mutant Parkinson's disease.

Lawrence I Golbe1, Giuseppe Di Iorio, Katerina Markopoulou, Aglaia Athanassiadou, Spiridon Papapetropoulos, Ray L Watts, Jeffery M Vance, Vincenzo Bonifati, Tanishia A Williams, John R Spychala, E Scot Stenroos, Williams G Johnson.   

Abstract

Monogenic forms of Parkinson's disease (PD) provide an opportunity to examine mechanisms underlying phenotypic variation. Glutathione S-transferase (GST) has detoxification and antioxidative functions. To screen genetic variations in GST for an effect on the onset age (OA) of PD, we typed seven common genetic polymorphisms in five GST isoenzymes, M1, M3, P1, T1, and Z1, in 36 affected individuals of Italian or Greek origin with the alpha-synuclein A53T (PARK1) mutation. Mean OA was 45.2 years with a wide SD of 11.03 years, similar to that of idiopathic PD. Our allelic analysis showed that the subjects homozygous for the GSTP1 G-for-A nucleotide substitution at position 313 had a mean OA acceleration of 15.2 years (31.3 +/- 7.09 years, n = 3 vs. 46.5 +/- 10.50 years, n = 33, P = 0.020). The GSTP1 C341T substitution was associated with a 9.7-year acceleration of OA, but the significance was borderline (36.4 +/- 8.35 years vs. 46.7 +/- 10.85 years, P = 0.0519). After correction for the five genes examined, both results lose statistical significance. Nevertheless, our results suggest that further investigation in GSTP1 variants and PD pathogenesis is warranted in sporadic PD and that a search for toxins that accelerate PD OA should pay particular attention to GST-P1 substrates. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17034008     DOI: 10.1002/ajmg.b.30450

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  6 in total

1.  Alterations in glutathione S-transferase pi expression following exposure to MPP+ -induced oxidative stress in the blood of Parkinson's disease patients.

Authors:  Ane Korff; Brenda Pfeiffer; Michelle Smeyne; Mehmet Kocak; Ronald F Pfeiffer; Richard Jay Smeyne
Journal:  Parkinsonism Relat Disord       Date:  2011-08-12       Impact factor: 4.891

2.  Identification of glutathione S-transferase pi as a protein involved in Parkinson disease progression.

Authors:  Min Shi; Joshua Bradner; Theo K Bammler; David L Eaton; Jianpeng Zhang; ZuCheng Ye; Angela M Wilson; Thomas J Montine; Catherine Pan; Jing Zhang
Journal:  Am J Pathol       Date:  2009-06-04       Impact factor: 4.307

3.  GSTpi expression in MPTP-induced dopaminergic neurodegeneration of C57BL/6 mouse midbrain and striatum.

Authors:  Margarida Castro-Caldas; Andreia Neves Carvalho; Isabel Peixeiro; Elsa Rodrigues; Maria Celeste Lechner; Maria João Gama
Journal:  J Mol Neurosci       Date:  2008-09-16       Impact factor: 3.444

Review 4.  Glutathione metabolism and Parkinson's disease.

Authors:  Michelle Smeyne; Richard Jay Smeyne
Journal:  Free Radic Biol Med       Date:  2013-05-08       Impact factor: 7.376

5.  GST P1, a novel downstream regulator of LRRK2, G2019S-induced neuronal cell death.

Authors:  Jie Chen; Anthony Liou; Lili Zhang; Zhongfang Weng; Yanqin Gao; Guodong Cao; Michael J Zigmond; Jun Chen
Journal:  Front Biosci (Elite Ed)       Date:  2012-06-01

6.  In vitro inhibition of glutathione-S-transferase by dopamine and its metabolites, 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylacetic acid.

Authors:  Rachel A Crawford; Kate R Bowman; Brianna S Cagle; Jonathan A Doorn
Journal:  Neurotoxicology       Date:  2021-07-24       Impact factor: 4.398

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.